Attached files
| file | filename |
|---|---|
| EX-31.2 - EXHIBIT 31.2 - Evelo Biosciences, Inc. | a12312019exhibit312.htm |
| EX-32.1 - EXHIBIT 32.1 - Evelo Biosciences, Inc. | a12312019exhibit321.htm |
| EX-31.1 - EXHIBIT 31.1 - Evelo Biosciences, Inc. | a12312019exhibit311.htm |
| EX-23.1 - EXHIBIT 23.1 - Evelo Biosciences, Inc. | a12312019exhibit231.htm |
| EX-21.1 - EXHIBIT 21.1 - Evelo Biosciences, Inc. | a12312019exhibit211.htm |
| EX-10.5 - EXHIBIT 10.5 - Evelo Biosciences, Inc. | a12312019exhibit105.htm |
| EX-10.4 - EXHIBIT 10.4 - Evelo Biosciences, Inc. | a12312019exhibit104.htm |
| EX-10.3 - EXHIBIT 10.3 - Evelo Biosciences, Inc. | a12312019exhibit103.htm |
| EX-4.3 - EXHIBIT 4.3 - Evelo Biosciences, Inc. | a12312019exhibit43.htm |
| 10-K - FORM 10-K - Evelo Biosciences, Inc. | evelo10-k12312019.htm |
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
I, Jonathan Poole, Chief Financial Officer of Evelo Biosciences, Inc. (the “Company”), hereby certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:
(1) | The Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2019 (the “Report”) fully complies with the requirements of Sections 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and |
(2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: February 14, 2020 | By: | /s/ Jonathan Poole | |||
Jonathan Poole | |||||
Chief Financial Officer | |||||
(Principal Financial and Accounting Officer) | |||||